# Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)

> **NCT01553279** · PHASE3 · COMPLETED · sponsor: **MCM Vaccines B.V.** · enrollment: 284 (actual)

## Conditions studied

- Neisseria Meningitidis
- Bacterial Infections
- Virus Diseases

## Interventions

- **BIOLOGICAL:** V419
- **BIOLOGICAL:** PREVNAR 13®
- **BIOLOGICAL:** MCC-TT
- **BIOLOGICAL:** MCC-CRM
- **BIOLOGICAL:** Hib-MCC
- **BIOLOGICAL:** MMR Vaccine

## Key facts

- **NCT ID:** NCT01553279
- **Lead sponsor:** MCM Vaccines B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03-30
- **Primary completion:** 2013-09-27
- **Final completion:** 2013-09-27
- **Target enrollment:** 284 (ACTUAL)
- **Last updated:** 2019-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01553279

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01553279, "Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT01553279. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*